Cardiovascular disease test kit BIOT-YG-I, FLI-600

h-FABPserumplasma

Introduction: hFABP is a kind of new cytoplasmic cell in cardiac that has high specificity, mainly expressed in cardiac. Once myocardial ischemic injury emerging, hFABP can be detected from the first to the third hour before pectoralgia happens, reach to the top level after the sixth to the eighth hour and recover to normal level from the 24th hour to the 30th hour. hFABP is a kind of soluble protein with relatively low molecular weight, it is widely found in human and animal multiple histocyte. At present, there are at least nine types of such proteins, such as small intestine protein, liver protein, kidney protein, heart protein and so on. hFABP is one of these proteins. It is specific to myocardial tissue, about 4% to 8% of the heart soluble protein. The expression level is extremely low or not expressed in other organizations. When myocardial ischemia is hypoxic or impaired, hFABP can be rapidly released into the blood. Therefore, hFABP is expected to develop an important index for early diagnosis of AMI and judgment of efficacy and prognosis of AMI thrombolysis. Advantage: The sample requirement is low, only 10μL of serum/plasma is required Clinical significance: 1. Detect early AMI with high sensitivity 2. Assess the area of myocardial infarction, detect myocardial infarction reperfusion and recurrence, etc. 3. As an important indicator of brain injury, nervous system disease, carbon monoxide poisoning diagnosis and treatment effect evaluation Intended use: ICU, Respiratory Medicine, Emergency department, Cardiology, Endocrinology, Nephrology